BioLineRx is trading 6.51% lower at $2.01, with broader market weakness the likeliest available context, though no stock-specific cause is confirmed. - No new company-specific announcement was found for October 14; its latest listed release was an October 8 announcement about GLIX1 presentations, which does not explain the decline. - Reuters reported September headline CPI of 3.7% year over year, above the 3.6% estimate; Treasury yields were rising alongside weaker U.S. stock futures.